Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Mark Fineman"'
Autor:
Robert R Henry, Juan P Frias, Brandon Walsh, Sharon Skare, John Hemming, Colleen Burns, Thomas A Bicsak, Alain Baron, Mark Fineman
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0203946 (2018)
OBJECTIVE:Metformin use is restricted in patients with renal impairment due to potential excess systemic accumulation. This study evaluated the glycemic effects and safety of metformin delayed-release (Metformin DR), which targets metformin delivery
Externí odkaz:
https://doaj.org/article/aa9b0c1870fa4d97b5a22f5e7b8c61fe
Autor:
Hassan Fadavi, Ioannis N. Petropoulos, Teresa Mixcoatl-Zecuatl, Katie E. Frizzi, Georgios Ponirakis, Maryam Ferdousi, Nigel A. Calcutt, Michael Zhang, Corinne G. Jolivalt, Andrew J.M. Boulton, Mitra Tavakoli, Mark Fineman, Nathan Efron, Shazli Azmi, Rayaz A. Malik, Andrew Marshall, Maria Jeziorska, Corinne A. Lee-Kubli
Publikováno v:
Diabetes, vol 66, iss 5
Marshall, A G, Lee-Kubli, C, Azmi, S, Zhang, M, Ferdousi, M, Mixcoatl-Zecuatl, T, Petropoulos, I N, Ponirakis, G, Fineman, M S, Fadavi, H, Frizzi, K, Tavakoli, M, Jeziorska, M, Jolivalt, C G, Boulton, A J M, Efron, N, Calcutt, N A & Malik, R A 2017, ' Spinal Disinhibition in Experimental and Clinical Painful Diabetic Neuropathy ', Diabetes, vol. 66, no. 5, pp. 1380-1390 . https://doi.org/10.2337/db16-1181
Diabetes
Marshall, A G, Lee-Kubli, C, Azmi, S, Zhang, M, Ferdousi, M, Mixcoatl-Zecuatl, T, Petropoulos, I N, Ponirakis, G, Fineman, M S, Fadavi, H, Frizzi, K, Tavakoli, M, Jeziorska, M, Jolivalt, C G, Boulton, A J M, Efron, N, Calcutt, N A & Malik, R A 2017, ' Spinal Disinhibition in Experimental and Clinical Painful Diabetic Neuropathy ', Diabetes, vol. 66, no. 5, pp. 1380-1390 . https://doi.org/10.2337/db16-1181
Diabetes
Impaired rate-dependent depression (RDD) of the Hoffman reflex is associated with reduced dorsal spinal cord potassium chloride cotransporter expression and impaired spinal γ-aminobutyric acid type A receptor function, indicative of spinal inhibitor
Autor:
Frank Pompilio, David M. Kendall, Mark Fineman, Marshall Grant, Gaurav Sharma, John A. Krueger
Publikováno v:
Diabetes. 68
Technosphere Insulin (TI) is an ultra-rapid, short-acting inhaled insulin that provides glycemic control in patients with diabetes. This ongoing, 2-part, open-label, interventional study aims to assess the efficacy and safety of TI in children aged 4
Publikováno v:
Diabetes, Obesity and Metabolism. 19:1499-1501
The history of Metformin-Associated Lactic Acidosis (MALA) is rooted in the earlier experience with phenformin, another biguanide treatment for type 2 diabetes that was removed from the market owing to a clear causal association with cases of lactic
Autor:
Thomas A. Bicsak, Brandon Walsh, Mark Fineman, Juan P. Frias, Sharon Skare, Colleen Burns, John Hemming, Alain D. Baron, Robert R. Henry
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0203946 (2018)
PLoS ONE
PLoS ONE
Objective Metformin use is restricted in patients with renal impairment due to potential excess systemic accumulation. This study evaluated the glycemic effects and safety of metformin delayed-release (Metformin DR), which targets metformin delivery
Publikováno v:
Diabetes, Obesity & Metabolism
Aims Metformin is renally excreted and has been associated with the development of lactic acidosis. Although current advice is to omit metformin during illnesses that may increase the risk of acute kidney injury (AKI), the evidence supporting this is
Autor:
Lisa Porter, Sylvia K. Shenouda, Guntram Schernthaner, Mark Fineman, Cory R. Heilmann, Michael A. Nauck, Aijun Gao, Thomas Forst, Wayne Huey-Herng Sheu, John B. Buse, Byron J. Hoogwerf, Marilyn K. Boardman
Publikováno v:
The Lancet. 381:117-124
Glucagon-like peptide-1 receptor agonists exenatide and liraglutide have been shown to improve glycaemic control and reduce bodyweight in patients with type 2 diabetes. We compared the efficacy and safety of exenatide once weekly with liraglutide onc
Autor:
Mark Fineman, Alain D. Baron, Sharon Skare, John B. Buse, Ralph A. DeFronzo, Terri Kim, Colleen Burns
Publikováno v:
Diabetologia
Aims/hypothesis Delayed-release metformin (Metformin DR) was developed to maximise gut-based mechanisms of metformin action by targeting the drug to the ileum. Metformin DR was evaluated in two studies. Study 1 compared the bioavailability and effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::198c437b14de047a32dbeed1d5a5a700
Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing
Autor:
Prajakti A. Kothare, Kenneth F. Mace, Wen-I Li, Kristin Taylor, Brandon Walsh, Mark Fineman, Brenda Cirincione, Maria Aisporna, Michaela Diamant, Leigh MacConell, Shawn Flanagan, Larry Z. Shen
Publikováno v:
Clinical Pharmacokinetics, 50(1), 65-74. Adis International Ltd
Fineman, M, Flanagan, S, Taylor, K, Aisporna, M, Shen, L Z, Mace, K F, Walsh, B, Diamant, M, Cirincione, B, Kothare, P, Li, W I & MacConell, L 2011, ' Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing ', Clinical Pharmacokinetics, vol. 50, no. 1, pp. 65-74 . https://doi.org/10.2165/11585880-000000000-00000
Fineman, M, Flanagan, S, Taylor, K, Aisporna, M, Shen, L Z, Mace, K F, Walsh, B, Diamant, M, Cirincione, B, Kothare, P, Li, W I & MacConell, L 2011, ' Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing ', Clinical Pharmacokinetics, vol. 50, no. 1, pp. 65-74 . https://doi.org/10.2165/11585880-000000000-00000
Exenatide is a glucagon-like peptide-1 receptor agonist, available in an immediate-release (IR), twice-daily formulation, which improves glycaemic control through enhancement of glucose-dependent insulin secretion, suppression of inappropriately elev
Autor:
Mark Fineman, Prajakti A. Kothare, Jaret Malloy, Xuesong Guan, Edmund V. Capparelli, Michael Gottschalk
Publikováno v:
Clinical Therapeutics. 31:806-815
This study assessed the pharmacokinetics, pharmacodynamics, and tolerability of single doses of exenatide in adolescent patients with type 2 diabetes mellitus (T2DM).This was a randomized, single-blind, dose-escalation, crossover study in adolescent